|
1
|
Rahman R, Asombang AW and Ibdah JA:
Characteristics of gastric cancer in Asia. World J Gastroenterol.
20:4483–4490. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Choi AH, Kim J and Chao J: Perioperative
chemotherapy for resectable gastric cancer: MAGIC and beyond. World
J Gastroenterol. 21:7343–8. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kawakami R, Mashima T, Kawata N, Kumagai
K, Migita T, Sano T, Mizunuma N, Yamaguchi K and Seimiya H:
ALDH1A3-mTOR axis as a therapeutic target for anticancer
drug-tolerant persister cells in gastric cancer. Cancer Sci.
111:962–973. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu X, Li M, Wang X, Dang Z, Yu L, Wang X,
Jiang Y and Yang Z: Effects of adjuvant traditional Chinese
medicine therapy on long-term survival in patients with
hepatocellular carcinoma. Phytomedicine. 62:1529302019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang Z, Qi F, Cui Y, Zhao L, Sun X, Tang W
and Cai P: An update on Chinese herbal medicines as adjuvant
treatment of anticancer therapeutics. Biosci Trends. 12:220–239.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yan S, Yue Y, Wang J, Li W, Sun M, Zeng L
and Wang X: Banxia Xiexin decoction, a traditional Chinese
medicine, alleviates colon cancer in nude mice. Ann Transl Med.
7:3752019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li K, Xu G, Liu C, Zhu B, Liu R, Hua B,
Zhang W and Feng X: Effect of a modified Banxia Xiexin decoction
plus chemotherapy on stage colon cancer. J Tradit Chin Med.
39:251–257. 2019.
|
|
9
|
Kim HR, Lee GS, Kim MS, Ryu DG, So HS,
Moon HC, Lee YR, Yang SH and Kwon KB: Effects of Banxia Xiexin
Decoction () on cisplatin-induced apoptosis of human A549 lung
cancer cells. Chin J Integr Med. 24:436–441. 2018. View Article : Google Scholar
|
|
10
|
Su L, Wang MM, Xu MR, Wang X, Xia HZ,
Zhang M, Zheng L, Zhu YD, Wang MQ and Li P: Banxia Xiexin Decoction
() Combined with Afatinib in treatment of advanced gallbladder
cancer: Case report and literature review. Chin J Integr Med.
25:303–306. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu XP, Ll PQ, Ming HX, Zhang W, Wang Q,
Chen YW and Yang BL: Effects of Banxia Xiexin Decoction containing
serum on proliferation, invasion and metastasis of gastric cancer
peritoneal metastasis cell line GC9811-P. Zhongguo Zhong Xi Yi Jie
He Za Zhi. 36:1224–1228. 2016.In Chinese. PubMed/NCBI
|
|
12
|
Yu Y, Zhang G, Han T and Huang H: Analysis
of the pharmacological mechanism of Banxia Xiexin decoction in
treating depression and ulcerative colitis based on a biological
network module. BMC Complement Med Ther. 20:1992020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang M, Chen J, Xu L, Shi X, Zhou X, An R
and Wang X: A network pharmacology approach to uncover the
molecular mechanisms of herbal formula Ban-Xia-Xie-Xin-Tang. Evid
Based Complement Alternat Med. 2018:40507142018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li C, Deng L, Shen H, Meng Q, Qian A, Sang
H, Xia J and Li X: O-6-methylguanine-DNA methyltransferase inhibits
gastric carcinoma cell migration and invasion by downregulation of
matrix metalloproteinase 2. Anticancer Agents Med Chem.
16:1125–1132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nowicki TS, Hu-Lieskovan S and Ribas A:
Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer J.
24:47–53. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen L, Diao L, Yang Y, Yi X, Rodriguez
BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, et al:
CD38-mediated immunosuppression as a mechanism of tumor cell escape
from PD-1/PD-L1 blockade. Cancer Discov. 8:1156–1175. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pitt JM, Vétizou M, Daillère R, Roberti
MP, Yamazaki T, Routy B, Lepage P, Boneca IG, Chamaillard M,
Kroemer G and Zitvogel L: Resistance mechanisms to
immune-checkpoint blockade in cancer: Tumor-intrinsic and
-extrinsic factors. Immunity. 44:1255–1269. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang Y, Xiang C, Wang Y, Duan Y, Liu C
and Zhang Y: PD-L1 promoter methylation mediates the resistance
response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI
resistance. Oncotarget. 8:101535–101544. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zuo Y, Zheng W, Liu J, Tang Q, Wang SS and
Yang XS: MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance
of ovarian cancer cells. Neoplasma. 67:93–101. 2020. View Article : Google Scholar
|
|
20
|
Gong K, Gong ZJ, Lu PX, Ni XL, Shen S, Liu
H, Wang JW, Zhang DX, Liu HB and Suo T: PLAC8 overexpression
correlates with PD-L1 upregulation and acquired resistance to
chemotherapies in gallbladder carcinoma. Biochem Biophys Res
Commun. 516:983–990. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang X, Zeng Y, Qu Q, Zhu J, Liu Z, Ning
W, Zeng H, Zhang N, Du W, Chen C and Huang JA: PD-L1 induced by
IFN-gamma from tumor-associated macrophages via the JAK/STAT3 and
PI3K/AKT signaling pathways promoted progression of lung cancer.
Int J Clin Oncol. 22:1026–1033. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang W, Zhong Z, Luo C, Xiao Y, Li L,
Zhang X, Yang L, Xiao K, Ning Y, Chen L, et al: The
miR-26a/AP-2alpha/Nanog signaling axis mediates stem cell
self-renewal and temozolomide resistance in glioma. Theranostics.
9:5497–5516. 2019. View Article : Google Scholar :
|
|
23
|
Chen G, Yang Y, Liu M, Teng Z, Ye J, Xu Y,
Cai X, Cheng X, Yang J, Hu C, et al: Banxia xiexin decoction
protects against dextran sulfate sodium-induced chronic ulcerative
colitis in mice. J Ethnopharmacol. 166:149–156. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Percie du Sert N, Ahluwalia A, Alam S,
Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U,
Emerson M, et al: Reporting animal research: Explanation and
elaboration for the ARRIVE guidelines 2.0. PLoS Biol.
18:e30004112020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
26
|
Xiang Y, Guo Z, Zhu P, Chen J and Huang Y:
Traditional Chinese medicine as a cancer treatment: Modern
perspectives of ancient but advanced science. Cancer Med.
8:1958–1975. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vasan N, Baselga J and Hyman DM: A view on
drug resistance in cancer. Nature. 575:299–309. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Amatu A, Barault L, Moutinho C, Cassingena
A, Bencardino K, Ghezzi S, Palmeri L, Bonazzina E, Tosi F, Ricotta
R, et al: Tumor MGMT promoter hypermethylation changes over time
limit temozolomide efficacy in a phase II trial for metastatic
colorectal cancer. Ann Oncol. 27:1062–1067. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Y, Yang Y, Lu Y, Herman JG, Brock MV,
Zhao P and Guo M: Predictive value of CHFR and MLH1 methylation in
human gastric cancer. Gastric Cancer. 18:280–287. 2015. View Article : Google Scholar
|
|
30
|
Lei Y, Tang L, Hu J, Wang S, Liu Y, Yang
M, Zhang J and Tang B: Inhibition of MGMT-mediated autophagy
suppression decreases cisplatin chemosensitivity in gastric cancer.
Biomed Pharmacother. 125:1098962020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shen M, Xu Z, Xu W, Jiang K, Zhang F, Ding
Q, Xu Z and Chen Y: Inhibition of ATM reverses EMT and decreases
metastatic potential of cisplatin-resistant lung cancer cells
through JAK/STAT3/PD-L1 pathway. J Exp Clin Cancer Res. 38:1492019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cha JH, Chan LC, Li CW, Hsu JL and Hung
MC: Mechanisms controlling PD-L1 expression in cancer. Mol Cell.
76:359–370. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jiang X, Wang J, Deng X, Xiong F, Ge J,
Xiang B, Wu X, Ma J, Zhou M, Li X, et al: Role of the tumor
microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol
Cancer. 18:102019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim JM and Chen DS: Immune escape to
PD-L1/PD-1 blockade: Seven steps to success (or failure). Ann
Oncol. 27:1492–504. 2016. View Article : Google Scholar : PubMed/NCBI
|
